Daily Bio News Summary — 2026-09-29: AbbVie's Cerevel payoff, a $2B AstraZeneca stake and a four-IPO tape

A Tuesday harvest produced 51 items across nine free sources: PR Newswire FDA (15), Reuters Biopharma (10), BioSpace (9), MedCity News (6), Pharmaphorum (4), Fierce Pharma (3), STAT News (2), Fierce Biotech (1) and FDA Newsroom (1). The batch spans Sept. 1–29 rather than a single day: MedCity’s biopharma channel and the PR Newswire FDA feed had been returning zero parseable items on several recent runs, so this harvest cleared a backlog of items that were always inside the 30-day window but had never been written.

Every item cited below comes from harvested frontmatter alone. Where a headline carries a figure, that figure is quoted as the source framed it; nothing beyond it is asserted. Category split: 16 regulatory, 24 therapeutics, 6 business, 5 market.

FDA decisions: approvals, clearances, and one retraction

AbbVie collected the marquee regulatory win. BioSpace reports the company won FDA approval for its Parkinson’s drug from the $8.7 billion Cerevel takeover — the first product approval to come out of that acquisition (BioSpace, 2026-09-29). The FDA’s own newsroom also reported a first: an approval for the first treatment for MCT8 deficiency (FDA Newsroom, 2026-09-28).

Rare disease produced three more nods. Mirum Pharmaceuticals received an FDA nod for Atebrioz in an ultra-rare bone disease, which BioSpace frames as making three options available in that indication (BioSpace, 2026-09-28). Ultragenyx landed a Sanfilippo nod that BioSpace describes as helping the company regroup after a tough Angelman defeat (BioSpace, 2026-09-28). Scholar Rock picked up its first FDA nod, for a rare muscle-wasting disease, per Reuters (Reuters Biopharma, 2026-09-16).

Elsewhere in the agency’s ledger, Roche’s Gazyva secured an FDA nod in a second autoimmune indication (Fierce Pharma, 2026-09-28), while Merck and Daiichi Sankyo retracted an accelerated approval request for their lung cancer ADC (BioSpace, 2026-09-29) — a regulatory step backwards that mirrors the partners’ withdrawn filing reported the previous day.

Three device-and-diagnostics clearances rounded out the flow: Cepheid received FDA clearance for its Xpert respiratory panel (PR Newswire FDA, 2026-09-29), VertigoDx secured 510(k) clearance for its point-of-care vestibular diagnostic (PR Newswire FDA, 2026-09-29), and Insera Therapeutics received 510(k) clearance for its CLEAR aspiration system (PR Newswire FDA, 2026-09-28).

China-facing dealmaking dominates business news

The batch’s business spine runs through China. Eli Lilly forged a $3.35 billion alliance with China’s InnoCare (Pharmaphorum, 2026-09-29); Novo Nordisk added long-term obesity differentiation through a deal with Hengrui worth up to $2.6 billion (BioSpace, 2026-09-29); Merck paid $400 million up front for a cancer drug prospect from China-based SciBrunch (MedCity News, 2026-09-01). Reuters frames the pattern directly: US drugmakers turning to China for licensing deals (Reuters Biopharma, 2026-09-28). The week’s largest single figure was not China-facing at all — Novartis signed a deal worth up to $3.2 billion for Alteogen’s drug delivery technology (Reuters Biopharma, 2026-09-02).

Obesity and metabolic: one retreat, one European patent fight

Obesity was subtraction rather than addition on the clinical side: Roche cut its muscle-sparing obesity drug after a mid-stage disappointment (BioSpace, 2026-09-29). Reuters reports that weight-loss drug developers are lining up to tap the market as competition heats up (Reuters Biopharma, 2026-09-22), and that Mylan asked a US court to clear a Wegovy generic from Novo’s patent claims (Reuters Biopharma, 2026-09-25).

Oncology, immunology and radiopharma

The single biggest cheque was oncology-adjacent: AstraZeneca took a $2 billion stake in Summit Therapeutics, which BioSpace frames as clearing Summit’s financial overhang (BioSpace, 2026-09-29). Radiopharmaceutical dealmaking continued with Telix agreeing to buy rival ITM for $1.65 billion upfront (Pharmaphorum, 2026-09-29), against a backdrop BioSpace profiles as radioligand therapy rewriting cancer care (BioSpace, 2026-09-24).

Earlier-stage oncology financing was active: ai3Bio raised $48 million for a STING-pathway pipeline (Fierce Biotech, 2026-09-29), and Xyone Therapeutics dosed its first patient in a first-in-human trial of XYA02 (AT2021), a MUC1-C-targeted antibody-drug conjugate (PR Newswire FDA, 2026-09-29).

In immunology, Amgen reported a drug meeting the goals of a key test in a common autoimmune disease with no approved medicines (MedCity News, 2026-09-01), North Immunology completed a reverse merger carrying $180 million for a next-gen inflammation drug (MedCity News, 2026-09-01), and BioSpace profiled six immunology targets sustaining a mammoth I&I market (BioSpace, 2026-09-28). Mirum put Hepcludex in its sights with a hepatitis D readout (Pharmaphorum, 2026-09-29).

Gene therapy and rare disease

uniQure was the day’s sharpest negative move, falling on long-term Huntington’s gene therapy data (Pharmaphorum, 2026-09-29). On the access side, UCSF Benioff Children’s Hospitals became the first US qualified treatment center contracted to administer the individualized gene therapy WASKYRA (PR Newswire FDA, 2026-09-28). Decoy Therapeutics reported preclinical data supporting once-weekly intranasal dosing for its DCOY-CoV programme (PR Newswire FDA, 2026-09-29).

Public markets: four listings in one batch

The IPO window stayed open: City Therapeutics filed for a US IPO as biotech listings surge (Reuters Biopharma, 2026-09-24), Iambic Therapeutics, backed by Nvidia and QIA, filed for a US IPO (Reuters Biopharma, 2026-09-22), ADARx made its stock market debut with $535 million (MedCity News, 2026-09-01), and Electra’s upsized IPO landed $350 million for a new class of precision immunology drugs (MedCity News, 2026-09-01). Grifols told Reuters that a Canadian plasma licence suspension has no impact on ongoing operations (Reuters Biopharma, 2026-09-24), and BioNTech is closing sites in Germany after failing to secure a sale (Fierce Pharma, 2026-09-28).

Research and infrastructure

CSL tapped Amazon’s cloud unit to boost its research pipeline (Reuters Biopharma, 2026-09-29), and Pfizer and Moderna lost bids to escape a Bayer US mRNA patent lawsuit (Reuters Biopharma, 2026-09-29) — the batch’s main intellectual-property item. Novartis separately bought Sironax technology for $125 million to gain a way to get drugs into the brain (MedCity News, 2026-09-01).

What this batch is NOT telling us

• No Endpoints News. All 33 Endpoints candidates were re-fetched and every one rendered the site’s soft-paywall stub (“sign up to read” + “premium subscriber”) — the seventh consecutive run with no free Endpoints story. Where a free twin existed on BioSpace, Fierce or MedCity, the story is present above in its free form; where it did not (a Genentech-alumni startup launch, a Spark co-founder’s new biotech, an Enveda megaround, a Travere CEO interview), the story is simply absent rather than paywalled.
• No BioPharma Dive. Its homepage parser again produced zero items (inline dates unverifiable), so nothing is quoted from it.
• Nothing politically charged. A large set of candidates was dropped at parse time under the standing filter: SNAP and child-welfare cuts, MAHA health-data access, a vaccine-skepticism feature, both FDA-nominee confirmation stories, tobacco and menthol regulation items, WHO leadership succession, a White House drug-manufacturing stocktake, litigation over graduate-student visa lengths, and one op-ed on “regenerative medicine.” They are not summarised here, by rule.
• No AI-drug-discovery platform mega-rounds and no mega-cap M&A. The largest disclosed figures are licensing and equity-stake shaped; nothing in the batch is a multi-billion-dollar acquisition of a public company.
• No neurology or cardiology readouts beyond the Parkinson’s approval — the clinical readouts that did appear are concentrated in rare disease and immunology.

Reading order

1. AbbVie’s Juvmo approval (BioSpace, 2026-09-29) — the first fruit of the Cerevel acquisition.
2. AstraZeneca’s $2B stake in Summit (BioSpace, 2026-09-29) — the batch’s largest single cheque.
3. Novo–Hengrui, up to $2.6B (BioSpace, 2026-09-29) — the clearest read on obesity’s next format.
4. Roche cutting its muscle-sparing obesity drug (BioSpace, 2026-09-29) — the counterweight to the Novo deal.
5. Endpoints-free rare disease trio: Mirum’s Atebrioz nod, Ultragenyx’s Sanfilippo nod and the FDA’s first MCT8 treatment approval.

How to read the underlying articles

Each item above corresponds to a markdown file in src/content/news/. The canonical link for any story is its sourceUrl field; the harvested description field is the headline text as published by the source. Figures quoted here are headline figures, not figures verified against the article body.

All 51 items in this batch

1. “Roche cuts muscle-sparing obesity drug after mid-stage disappointment” — BioSpace, 2026-09-29
2. “Summit snags $2B investment from AstraZeneca, clearing financial overhang” — BioSpace, 2026-09-29
3. “Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal” — BioSpace, 2026-09-29
4. “AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover” — BioSpace, 2026-09-29
5. “Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC” — BioSpace, 2026-09-29
6. “Australia’s CSL taps Amazon’s cloud unit to boost research pipeline” — Reuters Biopharma, 2026-09-29
7. “Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit” — Reuters Biopharma, 2026-09-29
8. “uniQure falls on long-term Huntington’s gene therapy data” — Pharmaphorum, 2026-09-29
9. “Lilly forges $3.35bn alliance with China’s InnoCare” — Pharmaphorum, 2026-09-29
10. “Telix to buy radiopharma rival ITM for $1.65bn upfront” — Pharmaphorum, 2026-09-29
11. “Audien beams up William Shatner to boldly boost hearing aid biz” — Fierce Pharma, 2026-09-29
12. “ai3Bio buzzing with $48M for STING pathway targeting pipeline” — Fierce Biotech, 2026-09-29
13. “XYone Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of XYA02(AT2021), a Novel Antibody Drug Conjugate targeting MUC1-C” — PR Newswire FDA, 2026-09-29
14. “Packaging Compliance Labs Enters Pharmaceutical Testing Market with Dedicated Lab and Expert Leadership” — PR Newswire FDA, 2026-09-29
15. “Cepheid Receives FDA Clearance for Xpert® Respiratory Panel to Aid in the Diagnosis of Respiratory Tract Infection” — PR Newswire FDA, 2026-09-29
16. “BiomEdit’s First-of-its-Kind Engineered Bacterial Biologic for Poultry Receives Conditional Licensure from USDA” — PR Newswire FDA, 2026-09-29
17. “FastWave Medical Reports 96.4% Procedural Success in First-in-Human Study of Sola™ Coronary Laser IVL System” — PR Newswire FDA, 2026-09-29
18. “VertigoDx Secures FDA 510(k) Clearance for SmartVertigo® Point-of-Care Vestibular Diagnostic System” — PR Newswire FDA, 2026-09-29
19. “Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection” — PR Newswire FDA, 2026-09-29
20. “Publication of ROADS Phase 3 Clinical Trial Data in Journal of Clinical Oncology Recommends GammaTile® as a New Standard-of-Care Option for Newly Diagnosed Operable Brain Metastases1” — PR Newswire FDA, 2026-09-29
21. “Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program” — PR Newswire FDA, 2026-09-29
22. “Implantica’s RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception” — PR Newswire FDA, 2026-09-29
23. “Implantica’s RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception” — PR Newswire FDA, 2026-09-29
24. “FDA Approves First Treatment for MCT8 Deficiency” — FDA Newsroom, 2026-09-28
25. “FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease” — BioSpace, 2026-09-28
26. “6 immunology targets to sustain a mammoth I&I market” — BioSpace, 2026-09-28
27. “US drugmakers turn to China for licensing deals” — Reuters Biopharma, 2026-09-28
28. “Roche’s Gazyva secures FDA nod in 2nd autoimmune indication” — Fierce Pharma, 2026-09-28
29. “BioNTech to close sites in Germany after failed sale” — Fierce Pharma, 2026-09-28
30. “Risk from toxic metals can persist months after wildfires, Maui study finds” — STAT News, 2026-09-28
31. “AI is eroding the barriers that kept biological weapons rare” — STAT News, 2026-09-28
32. “Fuse Oncology and Associated Medical Professionals of NY Launch Proof of Concept for End-to-End Radiation Oncology Workflow in Urology” — PR Newswire FDA, 2026-09-28
33. “Insera Therapeutics, Inc. Receives U.S. FDA 510(k) Clearance for the CLEAR™ Aspiration System Featuring Cyclical Aspiration” — PR Newswire FDA, 2026-09-28
34. “BRC Therapeutics Joins FDA and EMA Regulators at Workshop Advancing the Future of Botanical Drug Development” — PR Newswire FDA, 2026-09-28
35. “UCSF Benioff Children’s Hospitals Become the First US Qualified Treatment Center Contracted to Administer Individualized Gene Therapy WASKYRA®” — PR Newswire FDA, 2026-09-28
36. “Mylan asks US court to clear Wegovy generic from Novo patent claims” — Reuters Biopharma, 2026-09-25
37. “How radioligand therapy is rewriting cancer care” — BioSpace, 2026-09-24
38. “City Therapeutics files for US IPO as biotech listings surge” — Reuters Biopharma, 2026-09-24
39. “Grifols says Canada plasma license suspension has no impact on ongoing operations” — Reuters Biopharma, 2026-09-24
40. “Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on” — Reuters Biopharma, 2026-09-22
41. “Weight-loss drug developers line up to tap lucrative market as competition heats up” — Reuters Biopharma, 2026-09-22
42. “Scholar Rock gets first FDA nod for rare muscle-wasting disease” — Reuters Biopharma, 2026-09-16
43. “Novartis signs deal worth up to $3.2 billion for Alteogen’s drug delivery technology” — Reuters Biopharma, 2026-09-02
44. “Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch” — MedCity News, 2026-09-01
45. “Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut” — MedCity News, 2026-09-01
46. “Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds” — MedCity News, 2026-09-01
47. “Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs” — MedCity News, 2026-09-01
48. “North Immunology Reverse Merger Comes With $180M for Next-Gen Inflammation Drug” — MedCity News, 2026-09-01
49. “Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M” — MedCity News, 2026-09-01
50. “Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat” — BioSpace, 2026-09-28
51. “Mirum puts Hepcludex in its sights with hep D readout” — Pharmaphorum, 2026-09-29